Logo image of BTMD

BIOTE CORP -A (BTMD) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:BTMD - US0906831039 - Common Stock

2.27 USD
+0.01 (+0.44%)
Last: 1/21/2026, 11:52:57 AM

BTMD Key Statistics, Chart & Performance

Key Statistics
Market Cap103.65M
Revenue(TTM)195.65M
Net Income(TTM)28.79M
Shares45.66M
Float27.96M
52 Week High5.93
52 Week Low2.19
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)0.87
PE2.61
Fwd PE8.67
Earnings (Next)03-10
IPO2021-03-02
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
BTMD short term performance overview.The bars show the price performance of BTMD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

BTMD long term performance overview.The bars show the price performance of BTMD in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of BTMD is 2.27 USD. In the past month the price decreased by -17.82%. In the past year, price decreased by -58.98%.

BIOTE CORP -A / BTMD Daily stock chart

BTMD Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

BTMD Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to BTMD. BTMD has an average financial health and profitability rating.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BTMD Financial Highlights

Over the last trailing twelve months BTMD reported a non-GAAP Earnings per Share(EPS) of 0.87. The EPS increased by 190% compared to the year before.


Industry RankSector Rank
PM (TTM) 14.72%
ROA 25.87%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-33.33%
Sales Q2Q%-6.67%
EPS 1Y (TTM)190%
Revenue 1Y (TTM)-18.44%

BTMD Forecast & Estimates

11 analysts have analysed BTMD and the average price target is 4.94 USD. This implies a price increase of 117.63% is expected in the next year compared to the current price of 2.27.

For the next year, analysts expect an EPS growth of 229.18% and a revenue growth -3.44% for BTMD


Analysts
Analysts81.82
Price Target4.94 (117.62%)
EPS Next Y229.18%
Revenue Next Year-3.44%

BTMD Ownership

Ownership
Inst Owners63.14%
Ins Owners10.06%
Short Float %4.31%
Short Ratio8.06

About BTMD

Company Profile

BTMD logo image biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas and currently employs 217 full-time employees. The company went IPO on 2021-03-02. The firm provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The company also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.

Company Info

BIOTE CORP -A

1875 W. Walnut Hill Ln #100, Floor 5

Irving TEXAS US

Employees: 217

BTMD Company Website

BTMD Investor Relations

Phone: 19724869346

BIOTE CORP -A / BTMD FAQ

Can you describe the business of BIOTE CORP -A?

biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas and currently employs 217 full-time employees. The company went IPO on 2021-03-02. The firm provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The company also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.


Can you provide the latest stock price for BIOTE CORP -A?

The current stock price of BTMD is 2.27 USD. The price increased by 0.44% in the last trading session.


What is the dividend status of BIOTE CORP -A?

BTMD does not pay a dividend.


What is the ChartMill technical and fundamental rating of BTMD stock?

BTMD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


What is the analyst forecast for BTMD stock?

11 analysts have analysed BTMD and the average price target is 4.94 USD. This implies a price increase of 117.63% is expected in the next year compared to the current price of 2.27.


What is the employee count for BTMD stock?

BIOTE CORP -A (BTMD) currently has 217 employees.


What is the next earnings date for BTMD stock?

BIOTE CORP -A (BTMD) will report earnings on 2026-03-10, after the market close.